Actively Recruiting
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Led by Qianfoshan Hospital · Updated on 2025-07-04
140
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
Sponsors
Q
Qianfoshan Hospital
Lead Sponsor
S
Shanghai Pulmonary Hospital, Shanghai, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the immune and inflammatory processes involved in allergic bronchopulmonary aspergillosis (ABPA) to better understand how the condition progresses. The study aims to classify the disease into precise types based on inflammation and identify biomarkers linked to these types. It also explores the clinical outcomes related to different inflammatory patterns in ABPA. This observational study does not involve any treatment or intervention. Participants include those diagnosed with ABPA, fungal-sensitized asthma, or healthy controls. The study will monitor participants over a period of up to 12 months to assess immune markers related to the condition. During the study, researchers will measure total serum IgE levels as the primary outcome and Aspergillus-specific IgE and IgG as secondary outcomes. Participants will undergo assessments to monitor these markers periodically. The study is designed to include adults aged 18 years and older and will observe participants' immune responses without providing any investigational treatment.
CONDITIONS
Brief Title
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis
- Meets the diagnostic criteria for fungal-sensitized asthma
You will not qualify if you...
- Human immunodeficiency virus infection
- Malignant tumor
- Blood system disease
- Autoimmune system disease
- History of pulmonary tuberculosis
- Patients with a history of smoking or still smoking
- Invasive pulmonary fungal disease
- Contraindications to electronic bronchoscopy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants are observed and measurements including total serum IgE and Aspergillus-specific antibodies are collected over time.
Periodic visits during the 12 months
Trial Site Locations
Total: 1 location
1
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Jinan, Shandong, China, 250014
Actively Recruiting
Research Team
Q
Qian Qi, Prof.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here